ORIC241115P17500
- 0.00
- 0.000.00%
Oric Pharmaceuticals Newsroom
JonesTrading Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $17
Oric Pharmaceuticals Reports Q3 EPS (49c), Consensus (48c)
Promising Advancements in Cancer Treatment: Buy Rating for ORIC Pharmaceuticals
Oric Pharmaceuticals | 10-Q: Quarterly report
Express News | Oric Pharmaceuticals Inc: Cash and Investments of $282.4 Mln Expected to Fund Operating Plan Into Late 2026
Press Release: ORIC(R) Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates
Express News | Oric Pharmaceuticals Q3 Basic EPS USD -0.49 Vs. IBES Estimate USD -0.48
Express News | Oric Pharmaceuticals Q3 Operating Expenses USD 38.318 Million
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
Express News | Oric® Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Wells Fargo Initiates Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $20
Oric Pharmaceuticals Initiated at Buy by Jones Trading
Express News | Oric Pharmaceuticals, Inc. : Wells Fargo Initiates Coverage With Overweight Rating and Target Price $20
JonesTrading Initiates Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $17
Oric Pharmaceuticals Presents Data on ORIC-114
Express News | ORIC Pharmaceuticals Announced The Presentation Of A Poster Highlighting ORIC-114, A Brain Penetrant, Orally Bioavailable, Irreversible EGFR/HER2 Inhibitor, To Treat EGFR Exon 20 Insertions And Other Atypical Mutations
Candid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to It's Board of Directors
ORIC Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Buy Rating Affirmed for Oric Pharmaceuticals Amid Promising Collaborations and Strategic Clinical Advances
OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration